Encapsulated glycolipid antigens for treatment of neoplastic diseases

US12337033B2Active Publication Date: 2025-06-24ENGENEIC MOLECULAR DELIVERY PTY LTD
View PDF 24 Cites 0 Cited by

Patent Information

Application Number
US17/420624
Authority / Receiving Office
US · United States
Patent Type
Patents(United States)
Current Assignee / Owner
Priority Date
2019-01-04
Filing Date
2020-01-06
Publication Date
2025-06-24
Estimated Expiration
2042-08-31

Smart Images

  • Figure US12337033-D00001
    Figure US12337033-D00001
  • Figure US12337033-D00002
    Figure US12337033-D00002
  • Figure US12337033-D00003
    Figure US12337033-D00003
Patent Text Reader

Abstract

Compositions and methods for treating cancer are provided. In particular, the compositions comprise an encapsulated CD1d-restricted invariant Natural Killer T (iNKT) cell antigen, such as glycosphingolipid, for example, α-galactosylceramide. Methods of administering the compositions in combination with a therapy that induces the death of neoplastic cells in the subject are provided.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Combination tumor treatment with drug-loaded, bispecific ligand-targeted minicells and interferon-gamma

    CN105658233A

  • Targeted delivery of drugs, therapeutic nucleic acids and functional nucleic acids to mammalian cells via intact killed bacterial cells

    US20080038296A1

  • Compositions and Methods for Targeted in Vitro and in Vivo Drug Delivery to Mammalian Cells Via Bacterially Derived Intact Minicells

    US20080051469A1

  • Therapeutic compositions and methods for antibody and fc-containing targeting molecule-based targeted delivery of bioactive molecules by bacterial minicells

    US20120207754A1

  • Targeting the tumor microenvironment using manipulated NKT cells

    US20140255363A1